• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pro-Dex's Return On Capital Employed Overview

    2/7/23 9:47:10 AM ET
    $PDEX
    Medical/Dental Instruments
    Health Care
    Get the next $PDEX alert in real time by email

    According to Benzinga Pro data Pro-Dex (NASDAQ:PDEX) posted a 18.31% decrease in earnings from Q1. Sales, however, increased by 1.76% over the previous quarter to $11.28 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Pro-Dex is not utilizing their capital as effectively as possible. In Q1, Pro-Dex earned $1.08 million and total sales reached $11.09 million.

    What Is Return On Capital Employed?

    Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Pro-Dex posted an ROCE of 0.04%.

    It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

    ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Pro-Dex is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

    For Pro-Dex, the positive return on capital employed ratio of 0.04% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

    Analyst Predictions

    Pro-Dex reported Q2 earnings per share at $0.24/share, which did not meet analyst predictions of $0.29/share.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $PDEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PDEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDEX
    SEC Filings

    View All

    Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    1/29/26 4:03:40 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Pro-Dex Inc.

    10-Q - PRO DEX INC (0000788920) (Filer)

    1/29/26 4:00:53 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    12/19/25 4:00:23 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Domingo Angelita Rebamontan was granted 18 shares, increasing direct ownership by 0.12% to 15,465 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    1/23/26 4:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Director Philp Katrina Marie Kramer was granted 3,100 shares, increasing direct ownership by 45% to 2,900 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/24/25 4:00:02 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Van Kirk Richard Lee Jr covered exercise/tax liability with 72 shares, decreasing direct ownership by 0.07% to 99,707 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:46:37 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

    IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for

    5/2/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Financials

    Live finance-specific insights

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

    IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

    11/2/23 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Pro-Dex Inc.

    SC 13D - PRO DEX INC (0000788920) (Filed by)

    10/17/23 5:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - PRO DEX INC (0000788920) (Subject)

    2/22/21 4:47:58 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care